Bureaucrats, editor, reviewer, Administrators
6,385
edits
OPRA: Difference between revisions
Jump to navigation
Jump to search
→Guidelines
No edit summary |
|||
| Line 42: | Line 42: | ||
==Guidelines== | ==Guidelines== | ||
* NCCN guidelines Version 4.2024: "In those patients who achieve a complete clinical response with no evidence of residual disease on digital rectal examination (DRE), rectal MRI, and direct endoscopic | * NCCN guidelines Version 4.2024: "In those patients who achieve a complete clinical response with no evidence of residual disease on digital rectal examination (DRE), rectal MRI, and direct endoscopic evaluation, a “watch and wait,” nonoperative (chemotherapy and/or RT) management approach may be considered in centers with experienced multidisciplinary teams. | ||
evaluation, a “watch and wait,” nonoperative (chemotherapy and/or RT) management approach may be considered in centers with experienced multidisciplinary teams. | |||
The degree to which risk of local and/or distant failure may be increased relative to standard surgical resection has not yet been adequately characterized. Decisions for | The degree to which risk of local and/or distant failure may be increased relative to standard surgical resection has not yet been adequately characterized. Decisions for | ||
nonoperative management (NOM) should involve a careful discussion with the patient of their risk tolerance" | nonoperative management (NOM) should involve a careful discussion with the patient of their risk tolerance" | ||